As progressive-minded ophthalmologists, we have one goal: outcomes. With the large number of baby boomer patients expecting exciting advances in cataract surgery, it is mandatory that we provide excellent postoperative visual acuity.

I use Bromday (bromfenac ophthalmic solution 0.09%; Ista Pharmaceuticals, Inc.) as my “go to” nonsteroidal antiinflammatory drug for the treatment of pain and inflammation after cataract surgery. Although it is an off-label indication, I also believe the agent is useful for the prevention of cystoid macular edema. The effectiveness and comfort as well as patients’ adherence with this product have led to my using it after all cataract surgeries—especially with premium IOLs. It has been well demonstrated in glaucoma patients that adherence to medical regimens drops off the more frequently the medications are dosed. With once-a-day dosing, Bromday is a pillar in my defense against postoperative inflammation. I combine Bromday, Durezol (difluprednate ophthalmic emulsion 0.05%; Alcon Laboratories, Inc.), and Vigamox (moxifloxacin HCI ophthalmic solution 0.5%; Alcon Laboratories, Inc.) and use them one, two, and three times per day, respectively. The results I see at the slit-lamp examination are remarkable, and patients really enjoy the “wow” factor.

As an example, I recently saw a patient at her 1-week postoperative appointment with a visual acuity of 20/20 and J1/2 OU after Tecnis Multifocal IOL (Abbott Medical Optics Inc., Santa Ana, CA) placement. It was as if she had won the lottery! She was elated. The bottom line is that patients talk to one another and the word is out. They expect results and fast.

Ehsan Sadri, MD, is a board-certified ophthalmologist and a fellowship-trained glaucoma and cataract surgeon in practice in Newport Beach, California. He is a consultant to Allergan, Inc., and Ista Pharmaceuticals, Inc. Dr. Sadri may be reached at (949) 642-3100; esadrii@gmail.com.